License and Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended								3 Months Ended		7 Months Ended
	Sep. 30, 2021	Aug. 31, 2021	Jul. 31, 2021	May 31, 2021	Apr. 30, 2021	Mar. 31, 2021	Feb. 28, 2021	Jul. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Jul. 30, 2021
Preferred stock, shares issued (in shares)									0			0	16,944,484
Milestone payment					$ 2,500,000		$ 1,000,000.0
Acquired IPR&D expense			$ 39,900,000								$ 200,000
Sale of stock, price per share									$ 8.00
Quarterly fee									$ 1,300,000
Delivery fee									200,000
Completion fee									200,000
Exercise fee									1,000,000.0
Accrued Upfront Fee									200,000
Royalty expense									$ 0
Maximum [Member]
Royalty Based on Net Sales of Licensed Products, Percentage									0.50%
Minimum [Member]
Royalty Based on Net Sales of Licensed Products, Percentage									0.30%
Payments to acquire royalty									$ 15,000,000.0
Research and Development [Member]
Quarterly fee									1,300,000
Research Development And Regulatory Milestone
Potential milestone payment									18,000,000.0
Series A Preferred Stock [Member]
Preferred stock, shares issued (in shares)								6,237,500
Shares issued, Fair value									$ 40,000,000.0
Common Stock [Member]
Shares repurchased									21,250,000
Shares repurchased, Fair value									$ 85,000
Adimab Assignment Agreement [Member]
Preferred stock, shares issued (in shares)								5,000,000
Potential milestone payment									4,000,000.0
Milestone payment	$ 4,000,000.0	$ 4,000,000.0		$ 2,500,000		$ 1,000,000.0
Research and development in process									$ 0	$ 1,000,000.0
Adimab Assignment Agreement [Member] | Maximum [Member]
Potential milestone payment								$ 24,600,000
Royalty percentage of sublicense consideration									55.00%
Adimab Assignment Agreement [Member] | Minimum [Member]
Royalty percentage of sublicense consideration									45.00%
Adimab Assignment Agreement [Member] | Research and Development [Member]
Recognized expense									$ 300,000	$ 200,000
Adimab Assignment Agreement [Member] | First Product [Member]
Potential milestone payment								16,500,000
Adimab Assignment Agreement [Member] | Second Product [Member]
Potential milestone payment								$ 8,100,000
Adimab Assignment Agreement [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued (in shares)								5,000,000	5,000,000
Shares issued, Fair value								$ 40,000,000.0
Adimab Assignment Agreement [Member] | Common Stock [Member]
Shares repurchased								21,250,000
Shares repurchased, Fair value								$ 85,000
Adimab Collaboration Agreement [Member]
Expenses									$ 400,000
Delivery fee									0
TSRI
Research and development in process									$ 900,000
Amount Paid As Pre Paid Funding For Research Plan		$ 1,500,000